Reviewing Metsera (MTSR) and The Competition

Metsera (NASDAQ:MTSR) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Metsera to similar businesses based on the strength of its earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Metsera and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metsera	N/A	-121.12%	-53.54%
Metsera Competitors	-1,425.99%	-589.65%	-28.81%

Valuation & Earnings

This table compares Metsera and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Metsera	N/A	-$209.13 million	-11.16
Metsera Competitors	$947.76 million	-$45.20 million	11.71

Metsera’s rivals have higher revenue and earnings than Metsera. Metsera is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.6% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Metsera and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metsera	1	3	4	0	2.38
Metsera Competitors	5929	12239	37704	1174	2.60

Metsera currently has a consensus target price of $55.75, suggesting a potential downside of 20.92%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.47%. Given Metsera’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Metsera has less favorable growth aspects than its rivals.

Summary

Metsera rivals beat Metsera on 10 of the 12 factors compared.

About Metsera

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.